B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
Interactions
TNFRSF17 has been shown to interact with the B-cell activating factor TNFSF13B. A conserved domain at the N-terminus, BCMA TALL-1 binding domain, is required for binding to the TNFSF13B.
J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
Read more here: https://xtalks.com/jjs-carvykti-and-bms-abecma-win-fda-approvals-for-earlier-use-in-multiple-myeloma-3790/
J&J’s Carvykti and BMS’ Abecma have won expanded FDA approvals for earlier use in multiple myeloma. While Carvykti has been approved as a second-line treatment for multiple myeloma, Abecma has been approved as a third-line option for the blood cancer. The BCMA-targeted CAR T-cell therapy rivals will continue to face off in the multiple myeloma market, with Carvykti expected to maintain its edge due to a better perceived efficacy.
#shorts #fda #oncology
published: 12 Apr 2024
What Is Multiple Myeloma?
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
published: 19 May 2023
Developing and Delivering New Cell and Gene Therapies
Dana-Farber’s Connell and O'Reilly Families Cell Manipulation Core Facility helps develop and deliver new cell and gene therapies for patients with cancer. Learn more: https://cmcf.dana-farber.org/services.html
published: 07 May 2024
Who is Eligible for CAR-T Therapy?
Learn about the eligibility criteria for CAR-T cell therapy.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree Univers...
published: 25 May 2023
These Drugs Help Kill Cancer
Learn about what IMiDs are, how they work, and how they help kill cancer cells.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes wit...
published: 05 May 2023
What are Bispecific Antibodies?
Learn about what bispecific antibodies are and how they work.
For more information check out this video: https://healthtree.org/myeloma/university/courses/Gm7HKyNXTCOamoYXsCZE
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to h...
published: 01 Jun 2023
Gérémy BLOT T cells expressing an anti–B cell maturation antigen chimeric antigen receptor cause
Examen d'immunologie
published: 21 Apr 2021
FDA Issues Letters to CAR T-Cell Therapy Makers to Include Boxed Warning
For more on this story: https://xtalks.com/fda-issues-letters-to-car-t-cell-therapy-makers-to-include-boxed-warning-3703/
The FDA has issued letters to CAR T-cell therapy makers requiring a boxed warning about the risk of secondary cancers on their labels. This will outline the risk of T-cell malignancies that may occur after treatment with BCMA and CD19-directed autologous CAR T-cell immunotherapies. The directive applies to all six commercial CAR T-cell therapies, which include Bristol Myers Squibb’s Abecma and Breyanzi, Kite Pharma’s Yescarta and Tecartus, Johnson & Johnson’s Carvykti and Novartis’ Kymriah.
#Featured #FDA #BoxedWarning #DrugLabel #CARTCellTherapy #CellandGeneTherapy #CellTherapy
published: 02 Feb 2024
Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma
Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.
published: 27 Jun 2024
Comprendre le myélome et ses traitements
Présenté par:
Dr Jean-Samuel Boudreault MD, FRCPC.
Directeur de l’unité d’auto-greffe de cellules souches hématopoiétique.
Hôpital du Sacré-Coeur de Montréal
Montréal, Québec
Read more here: https://xtalks.com/jjs-carvykti-and-bms-abecma-win-fda-approvals-for-earlier-use-in-multiple-myeloma-3790/
J&J’s Carvykti and BMS’ Abecma have ...
Read more here: https://xtalks.com/jjs-carvykti-and-bms-abecma-win-fda-approvals-for-earlier-use-in-multiple-myeloma-3790/
J&J’s Carvykti and BMS’ Abecma have won expanded FDA approvals for earlier use in multiple myeloma. While Carvykti has been approved as a second-line treatment for multiple myeloma, Abecma has been approved as a third-line option for the blood cancer. The BCMA-targeted CAR T-cell therapy rivals will continue to face off in the multiple myeloma market, with Carvykti expected to maintain its edge due to a better perceived efficacy.
#shorts #fda #oncology
Read more here: https://xtalks.com/jjs-carvykti-and-bms-abecma-win-fda-approvals-for-earlier-use-in-multiple-myeloma-3790/
J&J’s Carvykti and BMS’ Abecma have won expanded FDA approvals for earlier use in multiple myeloma. While Carvykti has been approved as a second-line treatment for multiple myeloma, Abecma has been approved as a third-line option for the blood cancer. The BCMA-targeted CAR T-cell therapy rivals will continue to face off in the multiple myeloma market, with Carvykti expected to maintain its edge due to a better perceived efficacy.
#shorts #fda #oncology
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lesson...
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Dana-Farber’s Connell and O'Reilly Families Cell Manipulation Core Facility helps develop and deliver new cell and gene therapies for patients with cancer. Lear...
Dana-Farber’s Connell and O'Reilly Families Cell Manipulation Core Facility helps develop and deliver new cell and gene therapies for patients with cancer. Learn more: https://cmcf.dana-farber.org/services.html
Dana-Farber’s Connell and O'Reilly Families Cell Manipulation Core Facility helps develop and deliver new cell and gene therapies for patients with cancer. Learn more: https://cmcf.dana-farber.org/services.html
Learn about the eligibility criteria for CAR-T cell therapy.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/my...
Learn about the eligibility criteria for CAR-T cell therapy.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• DOCTOR | FACILITY
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #immunotherapy #cartcelltherapy #car-t #eligibility #eligibilitycriteria #cancer #cancertreatment
Learn about the eligibility criteria for CAR-T cell therapy.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• DOCTOR | FACILITY
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #immunotherapy #cartcelltherapy #car-t #eligibility #eligibilitycriteria #cancer #cancertreatment
Learn about what IMiDs are, how they work, and how they help kill cancer cells.
Get exclusive access to the latest content as soon as it's filmed at https://w...
Learn about what IMiDs are, how they work, and how they help kill cancer cells.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Oliver Van Oekelen, MD | Icahn School of
medicine at Mount Sinai
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#shorts #myeloma #immunomodulatorydrugs #immunesystem #cancerdrugs #cancertreatment #myelomatreatment #immunotherapy #IMiDs
Learn about what IMiDs are, how they work, and how they help kill cancer cells.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Oliver Van Oekelen, MD | Icahn School of
medicine at Mount Sinai
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#shorts #myeloma #immunomodulatorydrugs #immunesystem #cancerdrugs #cancertreatment #myelomatreatment #immunotherapy #IMiDs
Learn about what bispecific antibodies are and how they work.
For more information check out this video: https://healthtree.org/myeloma/university/courses/Gm7HK...
Learn about what bispecific antibodies are and how they work.
For more information check out this video: https://healthtree.org/myeloma/university/courses/Gm7HKyNXTCOamoYXsCZE
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Luciano Costa, MD, PhD | University Of Alabama At Birmingham
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #antibody #bispecificantibody #tcell #immunotherapy #cancertreatment #cancer
Learn about what bispecific antibodies are and how they work.
For more information check out this video: https://healthtree.org/myeloma/university/courses/Gm7HKyNXTCOamoYXsCZE
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Luciano Costa, MD, PhD | University Of Alabama At Birmingham
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #antibody #bispecificantibody #tcell #immunotherapy #cancertreatment #cancer
For more on this story: https://xtalks.com/fda-issues-letters-to-car-t-cell-therapy-makers-to-include-boxed-warning-3703/
The FDA has issued letters to CAR T-c...
For more on this story: https://xtalks.com/fda-issues-letters-to-car-t-cell-therapy-makers-to-include-boxed-warning-3703/
The FDA has issued letters to CAR T-cell therapy makers requiring a boxed warning about the risk of secondary cancers on their labels. This will outline the risk of T-cell malignancies that may occur after treatment with BCMA and CD19-directed autologous CAR T-cell immunotherapies. The directive applies to all six commercial CAR T-cell therapies, which include Bristol Myers Squibb’s Abecma and Breyanzi, Kite Pharma’s Yescarta and Tecartus, Johnson & Johnson’s Carvykti and Novartis’ Kymriah.
#Featured #FDA #BoxedWarning #DrugLabel #CARTCellTherapy #CellandGeneTherapy #CellTherapy
For more on this story: https://xtalks.com/fda-issues-letters-to-car-t-cell-therapy-makers-to-include-boxed-warning-3703/
The FDA has issued letters to CAR T-cell therapy makers requiring a boxed warning about the risk of secondary cancers on their labels. This will outline the risk of T-cell malignancies that may occur after treatment with BCMA and CD19-directed autologous CAR T-cell immunotherapies. The directive applies to all six commercial CAR T-cell therapies, which include Bristol Myers Squibb’s Abecma and Breyanzi, Kite Pharma’s Yescarta and Tecartus, Johnson & Johnson’s Carvykti and Novartis’ Kymriah.
#Featured #FDA #BoxedWarning #DrugLabel #CARTCellTherapy #CellandGeneTherapy #CellTherapy
Présenté par:
Dr Jean-Samuel Boudreault MD, FRCPC.
Directeur de l’unité d’auto-greffe de cellules souches hématopoiétique.
Hôpital du Sacré-Coeur de Montréal
...
Présenté par:
Dr Jean-Samuel Boudreault MD, FRCPC.
Directeur de l’unité d’auto-greffe de cellules souches hématopoiétique.
Hôpital du Sacré-Coeur de Montréal
Montréal, Québec
Présenté par:
Dr Jean-Samuel Boudreault MD, FRCPC.
Directeur de l’unité d’auto-greffe de cellules souches hématopoiétique.
Hôpital du Sacré-Coeur de Montréal
Montréal, Québec
Read more here: https://xtalks.com/jjs-carvykti-and-bms-abecma-win-fda-approvals-for-earlier-use-in-multiple-myeloma-3790/
J&J’s Carvykti and BMS’ Abecma have won expanded FDA approvals for earlier use in multiple myeloma. While Carvykti has been approved as a second-line treatment for multiple myeloma, Abecma has been approved as a third-line option for the blood cancer. The BCMA-targeted CAR T-cell therapy rivals will continue to face off in the multiple myeloma market, with Carvykti expected to maintain its edge due to a better perceived efficacy.
#shorts #fda #oncology
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
Dana-Farber’s Connell and O'Reilly Families Cell Manipulation Core Facility helps develop and deliver new cell and gene therapies for patients with cancer. Learn more: https://cmcf.dana-farber.org/services.html
Learn about the eligibility criteria for CAR-T cell therapy.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• DOCTOR | FACILITY
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #immunotherapy #cartcelltherapy #car-t #eligibility #eligibilitycriteria #cancer #cancertreatment
Learn about what IMiDs are, how they work, and how they help kill cancer cells.
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Oliver Van Oekelen, MD | Icahn School of
medicine at Mount Sinai
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#shorts #myeloma #immunomodulatorydrugs #immunesystem #cancerdrugs #cancertreatment #myelomatreatment #immunotherapy #IMiDs
Learn about what bispecific antibodies are and how they work.
For more information check out this video: https://healthtree.org/myeloma/university/courses/Gm7HKyNXTCOamoYXsCZE
Get exclusive access to the latest content as soon as it's filmed at https://www.healthtree.org/myeloma/university HealthTree University for Multiple Myeloma, offers a comprehensive online myeloma curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and keep up to date on the latest advancements in treating myeloma!
Topics covered in HTU include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much much more. We've partnered with over 140 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.
Get updates on research in myeloma through our newsletter: https://healthtree.org/myeloma/community/newsletter
We'd like to thank our faculty who donated their time in creating these videos, including:
• Luciano Costa, MD, PhD | University Of Alabama At Birmingham
You can donate to HealthTree University for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/healthtree-10-year-anniversary-myeloma-campaign-2023/c440295?c_src=healthtree-university
Follow HealthTree:
Twitter: https://www.twitter.com/healthtreeformm
Facebook: https://www.facebook.com/healthtreeformultiplemyeloma
Instagram: https://www.instragram.com/healthtreeformultiplemyeloma
#short #shorts #myeloma #myelomatreatment #antibody #bispecificantibody #tcell #immunotherapy #cancertreatment #cancer
For more on this story: https://xtalks.com/fda-issues-letters-to-car-t-cell-therapy-makers-to-include-boxed-warning-3703/
The FDA has issued letters to CAR T-cell therapy makers requiring a boxed warning about the risk of secondary cancers on their labels. This will outline the risk of T-cell malignancies that may occur after treatment with BCMA and CD19-directed autologous CAR T-cell immunotherapies. The directive applies to all six commercial CAR T-cell therapies, which include Bristol Myers Squibb’s Abecma and Breyanzi, Kite Pharma’s Yescarta and Tecartus, Johnson & Johnson’s Carvykti and Novartis’ Kymriah.
#Featured #FDA #BoxedWarning #DrugLabel #CARTCellTherapy #CellandGeneTherapy #CellTherapy
Présenté par:
Dr Jean-Samuel Boudreault MD, FRCPC.
Directeur de l’unité d’auto-greffe de cellules souches hématopoiétique.
Hôpital du Sacré-Coeur de Montréal
Montréal, Québec
B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
Interactions
TNFRSF17 has been shown to interact with the B-cell activating factor TNFSF13B. A conserved domain at the N-terminus, BCMA TALL-1 binding domain, is required for binding to the TNFSF13B.